Industry Growth Insights published a new data on “Pharmacogenomics Technology (Theranostics & CDx) Market”. The research report is titled “Pharmacogenomics Technology (Theranostics & CDx) Market research by Types (Instruments, Reagents and Consumables, Other), By Applications (Tumour, Diabetes, Mental Illness, Cardiovascular Disease, Other), By Players/Companies Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific, Qiagen, Guardant Health, MGI Tech, Amoy Diagnostics, BGI Group”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pharmacogenomics Technology (Theranostics & CDx) Market Research Report
By Type
Instruments, Reagents and Consumables, Other
By Application
Tumour, Diabetes, Mental Illness, Cardiovascular Disease, Other
By Companies
Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific, Qiagen, Guardant Health, MGI Tech, Amoy Diagnostics, BGI Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
202
Number of Tables & Figures
142
Customization Available
Yes, the report can be customized as per your need.
Global Pharmacogenomics Technology (Theranostics & CDx) Market Report Segments:
The global Pharmacogenomics Technology (Theranostics & CDx) market is segmented on the basis of:
Types
Instruments, Reagents and Consumables, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Tumour, Diabetes, Mental Illness, Cardiovascular Disease, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Illumina
- F. Hoffmann-La Roche
- Agilent
- Abbott
- Thermo Fisher Scientific
- Qiagen
- Guardant Health
- MGI Tech
- Amoy Diagnostics
- BGI Group
Highlights of The Pharmacogenomics Technology (Theranostics & CDx) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Instruments
- Reagents and Consumables
- Other
- By Application:
- Tumour
- Diabetes
- Mental Illness
- Cardiovascular Disease
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pharmacogenomics Technology (Theranostics & CDx) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pharmacogenomics technology (theranostics and CDx) is a field of pharmacology that uses genomic sequencing to identify the genetic variants associated with drug response. This information can then be used to personalize treatment for individual patients.
Some of the major players in the pharmacogenomics technology (theranostics & cdx) market are Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific, Qiagen, Guardant Health, MGI Tech, Amoy Diagnostics, BGI Group.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pharmacogenomics Technology (Theranostics & CDx) Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Pharmacogenomics Technology (Theranostics & CDx) Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Pharmacogenomics Technology (Theranostics & CDx) Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size & Forecast, 2018-2028 4.5.1 Pharmacogenomics Technology (Theranostics & CDx) Market Size and Y-o-Y Growth 4.5.2 Pharmacogenomics Technology (Theranostics & CDx) Market Absolute $ Opportunity
Chapter 5 Global Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Type
5.2.1 Instruments
5.2.2 Reagents and Consumables
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Applications
6.2.1 Tumour
6.2.2 Diabetes
6.2.3 Mental Illness
6.2.4 Cardiovascular Disease
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pharmacogenomics Technology (Theranostics & CDx) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pharmacogenomics Technology (Theranostics & CDx) Analysis and Forecast
9.1 Introduction
9.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Type
9.6.1 Instruments
9.6.2 Reagents and Consumables
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Applications
9.10.1 Tumour
9.10.2 Diabetes
9.10.3 Mental Illness
9.10.4 Cardiovascular Disease
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pharmacogenomics Technology (Theranostics & CDx) Analysis and Forecast
10.1 Introduction
10.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Type
10.6.1 Instruments
10.6.2 Reagents and Consumables
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Applications
10.10.1 Tumour
10.10.2 Diabetes
10.10.3 Mental Illness
10.10.4 Cardiovascular Disease
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Type
11.6.1 Instruments
11.6.2 Reagents and Consumables
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Applications
11.10.1 Tumour
11.10.2 Diabetes
11.10.3 Mental Illness
11.10.4 Cardiovascular Disease
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pharmacogenomics Technology (Theranostics & CDx) Analysis and Forecast
12.1 Introduction
12.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Type
12.6.1 Instruments
12.6.2 Reagents and Consumables
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Applications
12.10.1 Tumour
12.10.2 Diabetes
12.10.3 Mental Illness
12.10.4 Cardiovascular Disease
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pharmacogenomics Technology (Theranostics & CDx) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Type
13.6.1 Instruments
13.6.2 Reagents and Consumables
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pharmacogenomics Technology (Theranostics & CDx) Market Size Forecast by Applications
13.10.1 Tumour
13.10.2 Diabetes
13.10.3 Mental Illness
13.10.4 Cardiovascular Disease
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pharmacogenomics Technology (Theranostics & CDx) Market: Competitive Dashboard
14.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Illumina
14.3.2 F. Hoffmann-La Roche
14.3.3 Agilent
14.3.4 Abbott
14.3.5 Thermo Fisher Scientific
14.3.6 Qiagen
14.3.7 Guardant Health
14.3.8 MGI Tech
14.3.9 Amoy Diagnostics
14.3.10 BGI Group